Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers

Acta Oncologica

Volumn 38, Issue 4, 1999, Pages 495-503

  Holte, Harald ^a,b   Sou, Zhenhe ^a   Smeland, Erlend B ^a   Kvaløy, Stein ^a   Langholm, Ruth ^a   Stokke, Trond ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; CHEMICAL FRACTIONATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; S PHASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032976729     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432040     Document Type: Article

References (33)

1. 1. Longo DL. What's the deal with follicular lymphomas? (editorial; comment) [see comments]. J Clin Oncol 1993; 11: 202-8.
2. 2. Rosenberg SA. Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J Clin Oncol 1985; 3: 299-310.
3. 3. Coiffier B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-26.
4. 4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma (see comments). N Engl J Med 1993; 328: 1002-6.
5. 5. Harris NL, Jaffe ES, Stein H, et al. A revised European -American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group (see comments). Blood 1994; 84: 1361-92.
6. 6. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [published erratum appears in Lancet 1988 Feb 13; 1(8581): 372]. Lancet 1988; 1: 292-3.
7. 7. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl Med 1993; 329: 987-94.
8. 8. Hermans J, Krol AD, van Groningen K, Kluin PM, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-3.
9. 9. Bastion Y, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 1994; 12: 1340-2.
10. 10. Christensson B, Lindemalm C, Johansson B, Mellstedt H, Tribukait B, Biberfeld P. Flow cytometric DNA analysis: a prognostic tool in non Hodgkin's lymphoma. Leuk Res 1989; 13: 307-14.
11. 11. Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492-6.
12. 12. Joensuu H, Ristamaki R, Soderstrom KO, Jalkanen S. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2167-75.
13. 13. Rehn S, Glimelius B, Strang P, Sundstrom C, Tribukait B. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin's lymphoma. Hematol Oncol 1990; 8: 1-12.
14. 14. Macartney JC, Camplejohn RS, Morris R, Hollowood K, Clarke D, Timothy A. DNA flow cytometry of follicular non-Hodgkin's lymphoma. J Clin Pathol 1991; 44: 215-8.
15. 15. Winter JN, Andersen J, Varíakojis D, et al. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Blood 1996; 88: 3919-25
16. 16. Palestro G, Pinch A, Chuisa L, et al. Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphoma assessed by DNA flow cytometry and Ki67. Leuk Lymphoma 1995; 19: 467-72.
17. 17. Kvaloy S, Marton PF, Kaalhus O, Hoie J, Foss Abrahamsen A, Godal T. 3H-thymidine uptake in B-cell lymphomas relationship to treatment response and survival. Scand J Haematol 1985; 34: 429-35.
18. 18. Gerdes J, Stein H, Pileri S, et al. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987; 2: 448-9.
19. 19. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 154: 223-35.
20. 20. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671-8.
21. 21. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
22. 22. Klemi PJ, Alanen K, Jalkanen S, Joensuu H. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma. Br J Cancer 1992, 66: 739-43.
23. 23. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's disease: Cotswolds meeting. Cancer Res 1971; 31: 1860-1.
24. 24. Kvaloy S, Godal T, Marton PF, Steen HB, Brennhovd IO, Foss Abrahamsen A. Spontaneous (3H)-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol 1981; 26: 221-34.
25. 25. Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB. Proliferation and apoptosis in malignant and normal B-cell non-Hodgkin's lymphomas. Br J Cancer 1998; 77: 1832-8.
26. 26. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
27. 27. De Angelis P, Stokke T, Smedshammer L, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo Br J Cancer 1995; 72: 307-11.
28. 28. Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res 1996; 56: 40-3.
29. 29. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
30. 30. Joensuu H, Klemi PJ, Soderstrom KO, Jalkanen S. Comparison of S-phase fraction, working formulation, and Kiel classification in non-Hodgkin's lymphoma. Cancer 1991; 68: 1564-71.
31. 31. Alanen KA, Klemi PJ, Joensuu H, Kujari H, Pekkala E. Comparison of fresh, ethanol-preserved, and paraffin-embedded samples in DNA flow cytometry. Cytometry 1989; 10: 81-5.
32. 32. Canellos GP. CHOP may have been part of the beginning but certainly not the end: Issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 1997; 15: 1713-6.
33. 33. Magrath IT. The treatment of pediatric lymphomas: paradigms to plagiarize? Ann Oncol 1997; 8: 7-14.